ZYLNONTA
Apr 28, 2023
Roche’s CD79b ADC POLIVY: Attempt to Change DLBCL Treatment Space
In recent years, the field of oncology has witnessed a remarkable transformation thanks to the groundbreaking innovation of antibody-drug conjugates (ADCs). These game-changing molecules have three key components: an antibody drug, a potent cytotoxic payload, and a specialized linker protein that binds them togethe...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
